Background/Aim: Surgery and chemotherapy treatments of human laryngeal squamous cell carcinoma (HLSCC) may fail due to metastasis, in which epithelial-mesenchymal transition (EMT) plays an important role. TRPP2, a nonselective cation channel, is expressed in various cell types and participates in many biological processes. Here, we show that TRPP2 enhanced metastasis by regulating EMT. Methods: We used immunohistochemistry, western blotting, Ca 2+ imaging, transwell and wound healing assays to investigate TRPP2 expression levels in HLSCC tissue, and the role of TRPP2 in invasion and metastasis of a human laryngocarcinoma cell line (Hep2 cell). Results: We found that TRPP2 protein expression levels were significantly increased in HLSCC tissue; higher TRPP2 levels were associated with decreased patient survival time and degree of differentiation and advanced clinical stage. Knockdown of TRPP2 by transfection with TRPP2 siRNA markedly suppressed ATP-induced Ca 2+ release, wound healing, and cell invasion in Hep2 cells. Moreover, TRPP2 siRNA significantly decreased vimentin expression but increased E-cadherin expression in Hep2 cells. In the EMT signalling pathway, TRPP2 siRNA significantly decreased Smad4, STAT3, SNAIL, SLUG and TWIST expression in Hep2 cells.
TRPP2 Enhances Metastasis by Regulating Epithelial-Mesenchymal Transition in Laryngeal Squamous Cell Carcinoma

Introduction
TRPP2 (transient receptor potential polycystic 2, previously known as polycystin-2, PC2, or PKD2), a nonselective cation channel encoded by the PKD2 gene, consists of four subunits, each including six transmembrane domains, and is located mainly in the endoplasmic membrane and plasma membranes with high Ca 2+ permeability [1, 2] . Previous studies have determined that TRPP2 interacts with polycystin-1 (PKD1) in the plasma membrane as a functional ion channel for cell adhesion and mechanosensation [3] . TRPP2 can be activated by epidermal growth factor (EGF) in the kidney epithelial cell line LLC-PK1 via coupling with the EGF receptor (EGFR), although a specific agonist or antagonist of TRPP2 remains unknown [4] . It is reported that TRPP2 contributes to the myogenic response in cerebral arteries [5] . Endoplasmic reticulum-resident TRPP2 reduces the Ca 2+ release from the endoplasmic reticulum upon apoptotic stimuli, thus protecting the cells from apoptosis [6] . However, the TRPP2 and PKD1 complex can exert its effect on the kidney epithelium in the pathway that controls epithelial proliferation, differentiation and apoptosis via regulating intracellular Ca 2+ [7] . TRPP2 is not only identified as a likely mutant target responsible for autosomal dominant polycystic kidney disease (ADPKD), but also widely expressed in various cells and participates in many activities relating to proliferation and differentiation, such as those involved in Alzheimer's disease, myocardial hypertrophy, arterial hypertension, and tumour formation [5, [8] [9] [10] [11] [12] [13] .
Head and neck cancer is the sixth most common carcinoma worldwide, severely deteriorating the health of elderly people [14, 15] . Laryngeal squamous cell carcinoma, one of the most common tumours in head and neck cancer, has a poor prognosis due to its uncontrolled invasion and metastasis under the presently available treatments, including surgery and chemotherapy. Recently, epithelial-mesenchymal transition (EMT) has been suggested to play an important role in the invasion and metastasis of cancer cells derived from epithelia [16] . According to the results of previous reports, during EMT, cells that have lost their junction proteins have disturbed cellular polarity, rebuilt cytoskeletal protein, and destroyed intercellular adhesion [17] . In addition, cells undergoing EMT express more mesenchymal markers, such as vimentin and α-smooth muscle actin (α-SMA), so that they acquire the capacity to invade adjacent normal tissues and spread to distant sites via blood or lymphatic vessels [18] . According to previously published studies, head and neck squamous cell carcinoma (HNSCC) as well as breast cancer are associated with EMT [19] [20] [21] . One of the markers of cells involved in EMT is cadherin (named for Ca 2+ -dependent adhesion), a protein superfamily. Cadherin constitutes the extracellular Ca 2+ binding domain, transmembrane proteins, and intracellular tails associated with a large number of adaptors and signalling proteins. Epithelial cadherin (E-cadherin), a member of the cadherin superfamily, is expressed by various cells during normal individual development [22] . After development, E-cadherin is responsible for tissue structure and cellular movement [22] . However, decreasing expression of E-cadherin is a critical factor in EMT processes and is associated with increased tumour cell invasion and metastasis [18] . Moreover, E-cadherin is thought by pathologists to be a prognostic indicator of many carcinomas because reduced E-cadherin expression parallels enhanced aggressiveness and dedifferentiation [18, 23] . Neural cadherin (N-cadherin) is thought to mediate growth cone motility in neurons [24] . However, different signalling pathways appear to be involved in EMT [25] [26] [27] . Unequivocally, transforming growth factor-β (TGF-β) is a major inducer of different subtypes of EMT, including development, fibrosis, and carcinogenesis, in various cells [28] . In particular, TGF-β plays a major role in carcinoma progression into a motile, invasive state in which cells migrate and form a metastasis during tumour development, whereas in the early stages of tumour growth, TGF-β may have a tumour suppressive effect by inducing growth arrest and apoptosis [18, 28, 29] . Hence, as natural intracellular receptors of TGF-β, many Smad proteins, such as Smad2, Smad3 and Smad4, are phosphorylated after TGF-β binding to regulate the transcription of related genes and may participate in EMT as well [28, 29] . In addition, previous reports have indicated that the transcription factor signal transducer and activator of transcription 3 (STAT3) can induce EMT in cancer cells through activation of TWIST gene expression by cooperating with the EGFR [30] . STAT3 has also been found to be involved in many types of cancers, such as breast and prostate cancers [25, 26] . Given all this evidence, we selected vimentin, E-cadherin, Smad4, and STAT3 as markers of the signalling pathway of EMT in the present study.
EMT is substantially involved in HNSCC [19] . TRPP2 likely participates in EMT and tumour metastasis. Thus, we hypothesise here for the first time that TRPP2 plays a role in regulating the proliferation, metastasis, and invasion of human laryngeal squamous cell carcinoma (HLSCC). A strong understanding of TRPP2 and its networking pathways regulating HLSCC metastasis would greatly assist in selecting drug combinations for treating such tumours. Here, we used immunohistochemical staining, western blotting, Ca 2+ imaging, small interfering (si)RNA transfection, and cell migration and invasion assays to test our hypothesis.
Materials and Methods
Cell culture
Hep2, a laryngeal squamous cell carcinoma line, was purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS) at 37 °C in a 5% CO 2 incubator. siRNA transfections were facilitated by Lipofectamine 2000. One day before the transfection, Hep2 was plated in six-well culture plates with FBS-free and antibiotic-free culture medium. Before the transfection, culture medium (500 μL) was added to each well. The confluency of the cells was controlled so that cells were approximately 80% confluent at the time of the transfection. The siRNA oligomer (200 nM) was diluted in 50 μL of Opti-MEM reduced-serum medium. Lipofectamine 2000 (2 μL) was diluted in 50 μL of Opti-MEM medium before use. After a 5-min incubation, the diluted siRNA oligomer and diluted Lipofectamine 2000 were combined, mixed, and incubated together for 20 min at room temperature. Finally, the siRNA-Lipofectamine 2000 complexes were added to the wells to transfect the cells. The medium was changed to that previously used (DMEM containing FBS) after 6 h. A western blotting assay was used to determine the transfection efficiency after 24 h.
Western blotting
Western blotting was performed as previously described [5] . The proteins were extracted from the lysates of Hep2 cells with a detergent extraction buffer that consisted of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM Na 2 EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride and leupeptin. Total proteins (30 μg) were loaded into each pocket of a 10% SDS-PAGE gel. Subsequently, we transferred the protein to a polyvinylidene difluoride membrane. Membranes with proteins were incubated with Tris-buffered saline tween containing 10% non-fat dried milk for 1 h at room temperature to block nonspecific binding sites. For immunoblots, the membrane containing the transferred proteins was incubated with their respective specific primary antibodies (sc-25749 for TRPP2, sc-373717 for vimentin, sc-8426 for E-cadherin, sc-393933 for N-cadherin, sc-482 for STAT3, sc-7966 for Smad4, sc-393172 for SNAIL, sc-166476 for SLUG, sc-15393 for TWIST; Santa Cruz Biotechnology, USA) (1:200) overnight at 4 °C and then incubated with horseradish peroxidase-conjugated secondary antibody. The immunosignal results were revealed using an ECL detection system (Thermo Fisher Scientific, Pittsburgh, PA, USA). The optical densities of protein bands were analysed by a free software Image J. All protein bands were normalized to β-tubulin located in the same lane and expressed as the relative optical density.
Immunohistochemistry
Human laryngeal carcinoma tissues from patients were obtained during clinical surgery. Specimens were collected with written informed consent from each participating patient and approval by Ethics Committee of Anhui Medical University. The procedures were performed consistent with the Declaration of Helsinki and Good Clinical Practice [15] . The surgical specimens were fixed with 4% paraformaldehyde and then sliced into 5-μm thick sections. The sections were deparaffinized and rehydrated. Subsequently, heat-mediated antigen retrieval was completed with citrate buffer in a microwave oven. Following a 10-min hydrogen peroxide (3%) incubation, endogenous peroxidase activity was destroyed. The incubation with an anti-TRPP2 antibody (sc-25749, Santa Cruz Biotechnology, USA) overnight at 4 °C was followed by incubation with an anti-rabbit secondary antibody. The specimens were processed with horseradish peroxidase and then with 3,3′-diaminobenzidine tetrahydrochloride. Subsequently, the sections were counterstained with hematoxylin. The primary antibody was omitted as a negative control. Finally, all images were captured using a light microscope. Integrated optical density (IOD) of the images were analyzed by Image Pro Plus 5.1 (Media Cybernetics, USA) software.
Wound healing assay
Hep2 cells were seeded in a 6-well plate in a 5% CO 2 incubator at 37 °C until confluent and then rinsed in PBS and cultured in low-serum medium (0.1% serum in DMEM) one day before the experiment. A wound was produced by a straight scratch with a 200-μL pipette tip. The pipette tip was kept at an angle of less than approximately 30 degrees to limit the width of the wound so that both wound edges could be imaged together. The Hep2 cells were then rinsed with PBS to remove the floating cells and cultured in normal medium supplemented with 10% FBS. Finally, a microscope (Nikon company, Japan) was used to capture images at the same position of each well 0 h, 12 h, and 24 h after the wound was created and at 37 °C. The relative distance of cell migration to the scratched area was measured (the wound area remaining after 24 h was subtracted from the original wound area at 0 h), and a healing percentage was calculated. This experiment was repeated four times.
Cell migration and invasion assay
Transwell chambers containing polycarbonate membrane filters with an 24-well 8-μm pore size (#3422, Corning Company, USA) were coated with Matrigel (BD354277, Becton Dickinson Company, USA). In each well, 40 µl of Matrigel was added to a insert and dried in a 37 °C incubator for 30 minutes to form a thin gel layer. DMEM (0.2 mL) was added to the upper chamber containing Hep2 cells, and the same medium (0.6 mL) supplemented with 15% FBS was added to the lower chamber. Hep2 cells were seeded in the insert at a density of 1x10 5 . Following a 48 h incubation in a 5% CO 2 incubator at 37 °C, we removed the transwell insert from the plate and used a cotton-tipped applicator to carefully rub off the remaining cells that have not migrated from the top of the membrane. The cells that had migrated through the membrane filter pores and stuck to the lower side of the filter membrane were fixed in paraformaldehyde and stained with 4', 6-diamidino-2-phenylindole (DAPI). Four randomly selected fields were captured using a fluorescence microscope (Nikon company, Japan) to calculate the number of cells that had successfully invaded and transmigrated the Matrigel. The results are expressed as the mean cell count of the four fields. ] i was measured using methods described elsewhere [13] . Briefly, the seeded Hep2 cells were loaded with 10 μmol/L Fluo-8 (Invitrogen, USA) with 0.02% pluronic acid F-127 (Sigma-Aldrich Co., USA) at 37 °C for 30 min. ATP (100 μmol/L) was used to evoke Ca 2+ release in a Ca 
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Statistical analysis
SigmaPlot software was used to perform the statistical analyses of two-tailed, unpaired Student's t-tests. All results are expressed as means ± SEM. A value of P < 0.05 was considered statistically significant.
Results
Increased TRPP2 expression in HLSCC tissues from patients HLSCC tissues were obtained from patients undergoing clinical surgery. As an initial and broad screening method, immunohistochemical analysis was used to investigate TRPP2 protein expression levels in HLSCC and the adjacent tissues from each patient. The results indicated that the TRPP2 protein expression level, represented as an IOD value, was significantly increased in HLSCC tissues compared with that in adjacent tissues (Fig. 1A-C) . A western blot analysis performed to confirm this result also showed that HLSCC tissues expressed more TRPP2 protein than did the adjacent tissues (Fig. 1F-G) .
The HLSCC specimens used in the immunohistochemical analysis were then classified using a clinical stage standard to investigate the relationship between the clinical stage and TRPP2 expression level. The results indicated that specimens in stage III expressed more TRPP2 protein than did specimens in both stages I and II together (Fig. 1D) . We also used a pathophysiology standard to classify HLSCC specimens into three groups based on their degree of differentiation to investigate the relationship between differentiation degree and TRPP2 protein expression level. The analysis showed that each of the three groups was significantly different from the other two and that the TRPP2 protein expression level increased as differentiation was reduced (Fig. 1E) . These results suggested that TRPP2 protein was highly expressed in HLSCC tissues, and that the TRPP2 expression level was positively correlated with clinical stage but negatively correlated with the degree of differentiation in HLSCC. 
Correlation of patient survival time with level of TRPP2
To investigate the correlation between the TRPP2 protein expression level and patient survival, we examined survival times for those patients with HLSCC who provided the specimens that were used for immunohistochemical analysis of TRPP2. We used the linear regression models to fit the immunohistochemical IOD data to find the demarcation point (0.344), respectively. The patients were placed into one of two groups (lower or higher). We found that for a survival time of 0 to 60 months, patients in the lower IOD group (i.e., <0.344) lived significantly longer than those in the higher IOD group (i.e., >0.344; P = 0.0026; Fig. 2 ). However, for survival times longer than 60 months, no statistical differences were detected between the two groups (Fig. 2) . These results indicated that for the first 0-60 months, patients with HLSCC having higher TRPP2 protein expression levels had shorter survival times than those having lower TRPP2 levels.
Role of TRPP2 in laryngocarcinoma Hep2 cell Ca
2+ release TRPP2 is a nonselective cation channel permeable to Ca 2+ and located in the endoplasmic reticulum membrane and the plasma membrane [1] . To identify the function of TRPP2 in Fig. 2 . Correlation between TRPP2 protein expression level and patient survival. Kaplan-Meier curves for the overall survival of patients with laryngocarcinoma according to the expression of TRPP2. Based on the ratio of the integrated optical density/total area of TRPP2 immunostaining in laryngocarcinoma tissues, patients were included in either a low density (<0.344) or high density (>0.344) group . The survival status of each patient was obtained during follow-up. The survival rate-time curves are shown as a black line (density <0.344) and a red line (density >0.344). Hep2 cells, we used a TRPP2-specific siRNA to suppress TRPP2 expression. Our western blot analysis indicated that TRPP2 siRNA successfully knocked down the expression of the TRPP2 protein (Fig. 3A-B) . Subsequently, Ca 2+ imaging was conducted to measure changes in [Ca 2+ ] i . Adenosine triphosphate (ATP) induces inositol 1,4,5-trisphosphate production by activating a purinergic G protein-coupled receptor, the P2Y receptor, in the plasma membrane. Our results showed that ATP (100 μM) evoked Ca 2+ release from Ca 2+ stores and strongly induced [Ca 2+ ] i increase in Hep2 cells in a Ca 2+ -free medium (Fig. 3C-D) . However, TRPP2 siRNA markedly suppressed the ATP-induced Ca 2+ release (Fig. 3C-D) . These results suggested that TRPP2 siRNA effectively suppressed TRPP2 expression and agonist-induced Ca 2+ release in Hep2 cells.
Role of TRPP2 in Hep2 cell migration and invasion
Migration and invasion are two major factors determining the pathophysiological stage and the state of deterioration in patients with carcinomas [31] and are critically involved in laryngocarcinoma recidivating and metastasis. Thus, we used TRPP2 siRNA to identify the role of TRPP2 in Hep2 cell migration and invasion. When Hep2 cells were transfected with TRPP2 siRNA, wound healing assay data indicated that their migration velocity markedly slowed down (Fig. 4) . Compared with that for the scrambled siRNA-transfected control cells, TRPP2 siRNA significantly reduced the velocity of Hep2 cell migration both 12 h and 24 h after transfection (Fig. 4A-B) .
To examine TRPP2 function in cell invasion, we cultured transfected Hep2 cells in Matrigel transwells with 8-μm pores to allow the cells to digest the matrix and move. Compared with the scrambled control siRNA, Hep2 cells transfected with TRPP2 siRNA moved more slowly through the matrix (Fig. 5) . These results indicated that TRPP2 participated in Hep2 cell migration and might promote Hep2 cells to secret digestive enzymes to enhance invasion and metastasis.
Role of TRPP2 in Hep2 cell EMT and the underlying signalling pathway
Vimentin and E-cadherin are two molecular markers for EMT [18] . During EMT, cells produce more vimentin but less E-cadherin. Therefore, E-cadherin is often selected as a prognostic marker for patients with many types of carcinomas. In our study, we used western blot analysis to elucidate the changes in vimentin, E-cadherin and N-cadherin. We found that compared to that in cells transfected with scrambled siRNA, vimentin was decreased but E-cadherin was significantly increased in TRPP2 siRNA-transfected Hep2 cells without the alteration of N-cadherin (Fig. 6A-C) , suggesting that TRPP2 was likely involved in the EMT process.
To further explore the EMT pathway related to TRPP2, we examined Smad4 and STAT3 protein expression levels in Hep2 cells. Compared with those in the scrambled control siRNA-transfected cells, the expression levels of both Smad4 and STAT3 were decreased in TRPP2 siRNA-transfected Hep2 cells (Fig. 7A-B) . These data suggested that TRPP2 might participate in Hep2 cell EMT via Smad4-and STAT3-dependent pathways. Additionally, the expression levels of several transcription factors, including SNAIL, SLUG and TWIST were investigated. The result showed that the expression levels of SNAIL, SLUG and TWIST were significantly suppressed in TRPP2 siRNA-transfected Hep2 cells (Fig. 8A-C) . 
Discussion
TRPP2, as a nonselective cation channel, is reportedly involved in several types of cancers, including breast and prostate cancers [32, 33] . In the present study, we elucidated the relationship between the expression levels of TRPP2 protein in specimens obtained from patients during surgical procedures and the clinical prognosis of these patients. The potential pathological roles of TRPP2 and the underlying mechanisms were also investigated in laryngocarcinoma Hep2 cells. Here, we reported the four following novel findings. (1) Specimens with higher TRPP2 expression levels (as determined using immunohistochemistry and western blot analyses) had a lower degree of differentiation and a more advanced clinical stage. siRNA significantly reduced ATP-induced Ca 2+ release, migration, and invasion compared with cells transfected with scrambled control siRNA. (4) TRPP2 siRNA markedly suppressed the expression levels of vimentin, Smad4, STAT3, SNAIL, SLUG and TWIST proteins in Hep2 cells, but increased E-cadherin expression without the alteration of N-cadherin. Overall, our data suggest that a high expression of TRPP2 may accelerate the metastasis of laryngeal squamous cell carcinoma by enhancing EMT through Smad4 and STAT3 pathways.
HLSCC is one of the most common carcinomas in HNSCC. Both surgery and chemotherapy approaches are often used to treat patients with HLSCC. However, the prognosis and 5-year survival rate are unsatisfactory because of uncontrolled invasion and metastasis. Previous studies have indicated that some proteins can be used as prognosis and diagnostic biomarkers for HLSCC, such as p53, EGFR and TGF-α [34, 35] . In the present study, we found that the TRPP2 expression level was markedly higher in tumour tissues than in adjacent tissues. Our results investigating the correlation between TRPP2 protein expression level and clinical stage, differentiation degree, or survival time indicated that specimens expressing more TRPP2 had a lower degree of differentiation, more advanced clinical stage, and shorter 5-year survival time. Hence, TRPP2 may be involved in the generation and deterioration of HLSCC, and can be considered a clinical diagnostic biomarker indicating early metastasis and prognosis for patients with HLSCC.
Metastasis, the process by which secondary tumours develop, is associated with EMT in which cell-cell contacts are lost and cellular phenotypes are changed. Recent accumulating evidence indicates that many types of ion channels are related to tumour EMT, especially Ca 2+ channels [33] . Similar studies have also determined that chelation of intracellular Ca 2+ can suppress EGF-induced EMT [31] . Additionally, the transient receptor potential, melastatinlike 7 (TRPM7) channel is a Ca 2+ permeable ion channel and is involved in breast cancer EMT [36] . The [Ca 2+ ] i has major effects on the cellular migration machinery. In the present study, Ca 2+ was considered as a regulator of cell behaviours, such as EMT. TRPP2 is a nonselective Ca 2+ -permeable cation channel located at both cell membrane and endoplasmic reticulum. Hep2 cells transfected with TRPP2 siRNA showed a decrease in the amplitude of the signal representing Ca 2+ released from the endoplasmic reticulum and decreased cell migration and invasion. Based on these novel findings, we propose that TRPP2 may participate in the regulation of intracellular Ca 2+ signalling to regulate the EMT process and be included in the list of channels involved in cellular metastasis, along with TRPV1, 2 and 6, TRPM1 and 8, and TRPC6.
Previous studies have determined that epithelial tumours with EMT are likely to have strongly increased invasion, metastasis, and proliferation. E-cadherin, present in many types of epithelial cells, and vimentin, a mesenchymal substance, are both markers of EMT. In our study, when TRPP2 protein expression was suppressed via transfection with specific siRNA in Hep2 cells, we found a marked increase in E-cadherin and decrease in vimentin expression levels, which indicated inhibited EMT. N-cadherin was not altered in TRPP2 siRNA transfected Hep2 cells. Hence, EMT is implicated in the development of laryngocarcinoma as well as breast and prostate cancers. These results also provided a significant advance in understanding the effects of TRPP2 on EMT through its role in Ca 2+ regulation. We suggest here for the first time that TRPP2 be added to the intricate network of EMT.
When EMT occurs, the expression of epithelial markers is suppressed, while the expression of mesenchymal markers is enhanced. This change is modulated via a series of factors, such as TGF-β/Smad and STAT pathways. The TGF-β/Smad pathway is associated with DNA methylation. A recent study has shown that disruption of TGF-β/Smad can contribute to DNA demethylation, reversal of epithelial morphology, and inhibition of invasion in breast cancer cells [37] . STAT3 is an oncogenic transcription factor that is activated for EMT in many human malignancies, such as breast tumour. STAT3 can upregulate the TWIST gene to induce EMT in cancer cells [38] and play a vital role in cell proliferation, invasion, and metastasis. Our results showed that Smad4 and STAT3 were both decreased in Hep2 cells transfected with TRPP2 siRNA accompanied with decreased expression of SNAIL, SLUG and TWIST. These results indicated that TRPP2 channel maybe involved in these pathways by regulating
